Company profile
Evommune, Inc.
NYSE:EVMNBiotechnology: Pharmaceutical Preparations
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06603220 | phase2 | completed | 2024-08-14 | 2025-05-08 | Evommune, Inc. | A Study Evaluating the Safety, Tolerability, and Efficacy of EVO756 in Adults With Chronic Inducible Urticaria |
| NCT06723405 | phase2 | completed | 2025-02-13 | 2025-11-17 | Evommune, Inc. | Efficacy Study of EVO301 in Moderate to Severe Atopic Dermatitis |
| NCT07150845 | phase2 | active_not_recruiting | 2025-08-26 | 2026-07-01 | Evommune, Inc. | Phase 2b Study of EVO756 in Adults With Atopic Dermatitis |
| NCT06873516 | phase2 | completed | 2025-03-20 | 2026-05-29 | Evommune, Inc. | Phase 2b Study of EVO756 in Adults With Moderate to Severe Chronic Spontaneous Urticaria (CSU) |
| NCT05579899 | phase2 | completed | 2022-09-27 | 2023-07-27 | Evommune, Inc. | Safety and Efficacy Study of EVO101 Topical Cream in Atopic Dermatitis |
FDA applications (0)
No records yet.